Nuvalent Inc (NUVL)
94.02
0.00 (0.00%)
Upcoming Events
Latest Headlines
Nuvalent (NUVL) PT Lowered to $172 at Bernstein SocGen Group
June 4, 2026 4:10 AM - StreetInsider
Form 4 Nuvalent, Inc. For: Jun 01 Filed by: Balcom Alexandra
June 3, 2026 4:31 PM - SEC Filing
Leerink Reiterates Outperform Rating on Nuvalent (NUVL)
June 3, 2026 6:19 AM - StreetInsider
Nuvalent (NUVL) Reiterated at Overweight by Cantor Fitzgerald
June 2, 2026 7:26 AM - StreetInsider
Form 4 Nuvalent, Inc. For: May 28 Filed by: Noci Darlene
June 1, 2026 4:34 PM - SEC Filing
Form 4 Nuvalent, Inc. For: May 28 Filed by: Miller Deborah Ann
June 1, 2026 4:33 PM - SEC Filing
Nuvalent (NUVL) Reiterated at Buy by Stifel on Ph1/2 ALKOVE-1 study Data
June 1, 2026 7:35 AM - StreetInsider
Nuvalent receives FDA priority review for cancer drug neladalkib
May 27, 2026 6:30 AM - StreetInsider
Nuvalent Announces Key Program and Business Updates, Strengthening Foundation for Global Leadership in ROS1- and ALK-positive NSCLC
May 27, 2026 6:30 AM - PR NewsWire
Nuvalent to present cancer drug trial data at ASCO meeting
May 21, 2026 5:36 PM - StreetInsider
Nuvalent Highlights Upcoming Data Presentations for Neladalkib and Zidesamtinib at the 2026 American Society of Clinical Oncology Annual Meeting
May 21, 2026 5:24 PM - PR NewsWire
Bernstein SocGen Group Starts Nuvalent (NUVL) at Outperform, Top Pick
May 21, 2026 4:23 PM - StreetInsider
Nuvalent (NUVL) PT Lowered to $151 at Guggenheim
May 8, 2026 7:22 AM - StreetInsider
Form 10-Q Nuvalent, Inc. For: Mar 31
May 7, 2026 6:38 AM - SEC Filing
Nuvalent, Inc. (NUVL) Misses Q1 EPS by 4c
May 7, 2026 6:36 AM - StreetInsider
Form 8-K Nuvalent, Inc. For: May 07
May 7, 2026 6:35 AM - SEC Filing
Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial Results
May 7, 2026 6:30 AM - PR NewsWire
Form 4 Nuvalent, Inc. For: May 04 Filed by: Porter James Richard
May 6, 2026 4:31 PM - SEC Filing
Form SCHEDULE 13G/A Nuvalent, Inc. Filed by: FMR LLC
May 6, 2026 11:30 AM - SEC Filing
Form 4 Nuvalent, Inc. For: May 01 Filed by: Balcom Alexandra
May 5, 2026 4:31 PM - SEC Filing
Form 4 Nuvalent, Inc. For: Apr 30 Filed by: Miller Deborah Ann
May 1, 2026 4:32 PM - SEC Filing
Form 4 Nuvalent, Inc. For: Apr 29 Filed by: Noci Darlene
May 1, 2026 4:30 PM - SEC Filing
Form 144 Nuvalent, Inc. Filed by: Miller Deborah Ann
April 30, 2026 4:29 PM - SEC Filing
Guardant Health partners with Nuvalent for cancer diagnostics development
April 30, 2026 8:06 AM - StreetInsider
Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infi
April 30, 2026 8:05 AM - BizWire
Form ARS Nuvalent, Inc. For: Dec 31
April 28, 2026 4:31 PM - SEC Filing
Form DEFA14A Nuvalent, Inc.
April 28, 2026 4:29 PM - SEC Filing
Form DEF 14A Nuvalent, Inc. For: Jun 16
April 28, 2026 4:28 PM - SEC Filing
Stifel: 'We believe these AACR datasets flex NUVL's medicinal chemistry prowess'
April 21, 2026 3:08 PM - StreetInsider
Nuvalent to Present Pivotal Data from ALKOVE-1 Trial of Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC at the 2026 American Society of Clinical Oncology Annual Meeting
April 21, 2026 10:33 AM - PR NewsWire
H.C. Wainwright Reiterates Buy Rating on Nuvalent (NUVL)
April 21, 2026 6:36 AM - StreetInsider
Nuvalent presents zidesamtinib data at AACR cancer research meeting
April 17, 2026 4:01 PM - StreetInsider
New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026
April 17, 2026 4:01 PM - PR NewsWire
Form 4 Nuvalent, Inc. For: Apr 09 Filed by: Pelish Henry E.
April 13, 2026 4:30 PM - SEC Filing
Bernstein on US Pharma and Biotech: Who might buy whom?
April 13, 2026 5:52 AM - StreetInsider
Form 4 Nuvalent, Inc. For: Apr 06 Filed by: Porter James Richard
April 8, 2026 4:30 PM - SEC Filing
Form 8-K Nuvalent, Inc. For: Apr 07
April 7, 2026 12:42 PM - SEC Filing
Nuvalent Announces Submission of New Drug Application to FDA for Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC
April 7, 2026 9:35 AM - PR NewsWire
Nuvalent submits FDA application for lung cancer drug neladalkib
April 7, 2026 6:32 AM - StreetInsider
Form 4 Nuvalent, Inc. For: Apr 01 Filed by: Balcom Alexandra
April 3, 2026 4:31 PM - SEC Filing
Form 4 Nuvalent, Inc. For: Apr 01 Filed by: Lane Benjamin
April 2, 2026 4:30 PM - SEC Filing
Form 4 Nuvalent, Inc. For: Mar 30 Filed by: Noci Darlene
April 1, 2026 4:32 PM - SEC Filing
Nuvalent (NUVL) Reiterated at Buy by Stifel After Meet with CEO, CFO
March 31, 2026 7:34 AM - StreetInsider
Form 144 Nuvalent, Inc. Filed by: Noci Darlene
March 30, 2026 5:59 PM - SEC Filing
Form 4 Nuvalent, Inc. For: Mar 26 Filed by: Miller Deborah Ann
March 30, 2026 5:36 PM - SEC Filing
Wells Fargo Starts Nuvalent (NUVL) at Overweight
March 30, 2026 8:08 AM - StreetInsider
Form SCHEDULE 13G/A Nuvalent, Inc. Filed by: VANGUARD GROUP INC
March 27, 2026 11:07 AM - SEC Filing
Form 4 Nuvalent, Inc. For: Mar 24 Filed by: Balcom Alexandra
March 26, 2026 4:31 PM - SEC Filing
Form 144 Nuvalent, Inc. Filed by: Balcom Alexandra
March 24, 2026 6:32 PM - SEC Filing
Form 3 Nuvalent, Inc. For: Mar 16 Filed by: Lane Benjamin
March 20, 2026 4:31 PM - SEC Filing
Nuvalent to Present New Preclinical and Clinical Data for Zidesamtinib, an Investigational ROS1-Selective Inhibitor, at AACR Annual Meeting 2026
March 17, 2026 5:16 PM - PR NewsWire
Form 4 Nuvalent, Inc. For: Mar 12 Filed by: Pelish Henry E.
March 16, 2026 4:32 PM - SEC Filing
Form 144 Nuvalent, Inc. Filed by: Pelish Henry E.
March 12, 2026 4:38 PM - SEC Filing
Form 4 Nuvalent, Inc. For: Mar 06 Filed by: Porter James Richard
March 10, 2026 4:31 PM - SEC Filing
Full Article List
